Tapimmune, Inc. (TPIV)

Oncology Corporate Profile

Stock Performance

3.2825
0.1725

3 Month Stock History Chart

HQ Location

1551 Eastlake Avenue East, Suite 100
Seattle, WA 98102

Company Description

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities.

Website: http://www.tapimmune.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TPIV 110immunotherapyBreast CancerII
TPIV 200immunotherapyPlatinum-resistant Ovarian cancerII
TPIV 200immunotherapyPlatinum-sensitive Ovarian cancerII
TPIV 200immunotherapyTriple negative Breast cancerII

View additional information on product candidates here »

Source: http://www.tapimmune.com

Recent News Headlines

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/20/2017 06:23 pm

8/8/2017 06:19 am

8/8/2017 06:19 am

8/8/2017 06:19 am

8/8/2017 06:19 am

7/18/2017 06:19 am

7/18/2017 06:19 am

7/18/2017 06:19 am

7/18/2017 06:19 am

6/27/2017 06:19 am

6/27/2017 06:19 am

6/27/2017 06:19 am

6/27/2017 06:19 am

6/27/2017 06:19 am

5/1/2017 06:19 am

4/28/2017 12:19 pm

4/27/2017 12:19 pm

4/19/2017 06:19 am

4/7/2017 06:17 am

4/7/2017 06:17 am